References
- Ahmed K, Al-Emran A, Jesmin T, et al (2013). Early detection of lung cancer risk using data mining. Asian Pac J Cancer Prev, 14, 595-8. https://doi.org/10.7314/APJCP.2013.14.1.595
- Bose P, Perkins EB, Honeycut C, et al (2012). Cancer Chemother Pharmacol, 69, 1657-67. https://doi.org/10.1007/s00280-012-1839-5
- Chen YT, Feng B, Chen LB, (2012). Update of research on drug resistance in small cell lung cancer chemotherapy. Asian Pacific J Cancer Prev, 13, 3577-81. https://doi.org/10.7314/APJCP.2012.13.8.3577
- Curran WJ, Paulus R, Langer CJ, et al (2011). Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer, randomized phase III trial RTOG 9410. J Natl Cancer Inst, 103, 1452-60. https://doi.org/10.1093/jnci/djr325
- Ginsberg RJ, Vokes EE, Raben A (1997). Non-small cell lung cancer. In, DeVita VT, Hellman S, Rosenberg SA, eds. Cancer, principles and practice of oncology. 4th ed. Philadelphia, PA, Lippincott-Raven, 858-910.
- He YQ, Zhou B, Shi SQ, et al (2012). Genetic Variation in PDCD6 and Susceptibility to Lung Cancer. Asian Pac J Cancer Prev, 13, 4689-93. https://doi.org/10.7314/APJCP.2012.13.9.4689
- Helsing M, Bergman B, Thaning L, et al (1998). Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre randomised phase III trial. Joint Lung Cancer Study Group. Eur J Cancer, 34, 1036-44. https://doi.org/10.1016/S0959-8049(97)10122-8
- Huang, Xiaoqin, Zheng, et al (2012). Microscopic binding of m5 muscarinic acetylcholine receptor with antagonists by homology modeling, molecular docking, and molecular dynamics simulation journal of physical chemistry b, 116, 532-41. https://doi.org/10.1021/jp210579b
- Kapetanoic IM (2008). Computer aided drug discovery and development, insilico-chemico-biological approach. Chem Biol Interact, 171, 165-76 https://doi.org/10.1016/j.cbi.2006.12.006
- Lynch TJ, Bell DW, Sordella R (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39. https://doi.org/10.1056/NEJMoa040938
- Mendelsohn J, Baselga J (2002). The EGF receptor family as targets for cancer therapy. Oncogene, 19, 6550-65.
- Molina JR, Yang P, Cassivi SD, et al (2008). Non-small cell lung cancer, epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc, 83, 584-94. https://doi.org/10.1016/S0025-6196(11)60735-0
- NSCLC Meta-Analyses Collaborative Group (2008). Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer, a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol, 26, 4617-25. https://doi.org/10.1200/JCO.2008.17.7162
- Rapp E, Pater JL, Willan A, et al (1988). Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer-report of a Canadian multicenter randomized trial. J Clin Oncol, 6, 633-41. https://doi.org/10.1200/JCO.1988.6.4.633
- Shukla RK, Tilak AR, Kumar C, et al (2013). Associations of CYP1A1, GSTM1 and GSTT1 polymorphisms with lung cancer susceptibility in a Northern Indian Population. Asian Pac J Cancer Prev, 14, 3345-9 https://doi.org/10.7314/APJCP.2013.14.5.3345
- Sun JY, Shi L, Gao XD, et al (2012). Physical activity and risk of lung cancer, a meta-analysis of prospective cohort studies. Asian Pac J Cancer Prev, 13, 3143-7. https://doi.org/10.7314/APJCP.2012.13.7.3143
- Thomas L, Doyle LA, Edelman MJ (2005). Lung cancer in women, emerging differences in epidemiology, biology, and therapy. Chest, 128, 370-381. https://doi.org/10.1378/chest.128.1.370
- Wolber, G, Langer, T (2005). 3-D Pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model, 45, 160-9. https://doi.org/10.1021/ci049885e